Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study
- PMID: 9816300
Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study
Abstract
Evidence for clinically significant radiosensitization by the halogenated pyrimidine 5-iododeoxyuridine (IdUrd) continues to accumulate. In vitro radiosensitization has been demonstrated in human colon tumor cell lines following exposure to 1-10 micrometer. Coadministration of leucovorin (LV) increases radiosensitization, which correlates directly with increased IdUrd DNA incorporation. Clinical data regarding proliferation rates and thymidine kinase levels in tumors versus normal tissues suggest selective incorporation of IdUrd into gastrointestinal tumors may occur. The objectives of this Phase I study were: (a) to assess the feasibility of LV modulation of IdUrd radiosensitization by determining the maximum tolerated dose (MTD) of IdUrd plus LV; and (b) to perform correlative laboratory studies to investigate the potential of IdUrd plus LV to increase radiosensitization in vivo. Seventeen patients with unresectable or recurrent gastrointestinal adenocarcinomas received a 14-day course of continuous i.v. infusion of IdUrd prior to initiation of radiotherapy. Two additional 14-day infusions of IdUrd with LV were given during the course of radiotherapy (60 Gy in 6 weeks). The initial dose of IdUrd was 250 mg/m2/day and was escalated in subsequent patients to 400 and 600 mg/m2/day. The LV dose remained fixed at 250 mg/m2/day. Leukopenia was the dose-limiting toxicity, and 400 mg/m2/day was the MTD for this trial. At the MTD, the mean +/- SD steady-state plasma concentration of IdUrd during the infusion, measured by high-performance liquid chromatography, was 0.66 +/- 0.23 micrometer. There was no significant influence of LV on IdUrd DNA incorporation in peripheral blood granulocytes as measured by high-performance liquid chromatography. Based on toxicity data and correlative laboratory studies, a meaningful increase in radiosensitization would not be achieved with the IdUrd infusion schedule and dose of LV investigated compared with IdUrd alone.
Similar articles
-
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.Cancer Res. 1998 Jul 1;58(13):2793-800. Cancer Res. 1998. PMID: 9661893 Clinical Trial.
-
Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.Cancer Res. 1988 May 15;48(10):2933-7. Cancer Res. 1988. PMID: 2965970
-
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.Cancer Res. 1993 Mar 15;53(6):1293-6. Cancer Res. 1993. PMID: 7680282 Clinical Trial.
-
Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers.Semin Oncol. 1992 Jun;19(3 Suppl 9):41-7. Semin Oncol. 1992. PMID: 1641656 Review.
-
The clinical rationale for S-phase radiosensitization in human tumors.Curr Probl Cancer. 1993 Sep-Oct;17(5):273-321. doi: 10.1016/0147-0272(93)90012-q. Curr Probl Cancer. 1993. PMID: 8281809 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources